Understanding how biological features affect immunotherapy response in lung cancer patients
PROPHETIC Extended - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Extended Study.
OncoHost Ltd. · NCT05736029
This study looks at how certain biological features in lung cancer patients can help predict who will benefit from immunotherapy treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 350 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | OncoHost Ltd. (industry) |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Dallas, Texas) |
| Trial ID | NCT05736029 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the mechanisms behind patient responses to immunotherapy in Non-Small Cell Lung Cancer (NSCLC). Researchers will collect biological samples, including plasma, PBMCs, stool, and tissue, from patients before and during their treatment. The study will analyze these samples for various biomarkers and clinical data to develop an algorithm that predicts which patients may benefit from immune checkpoint inhibitor therapies. The goal is to correlate specific biological features with treatment responses, clinical benefits, and adverse events.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with Non-Small Cell Lung Cancer who can provide informed consent.
Not a fit: Patients with concurrent active malignancies or significant mental impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for lung cancer patients receiving immunotherapy.
How similar studies have performed: While similar studies have explored biomarkers in cancer treatment, this specific multiomics approach to predict immunotherapy responsiveness is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Provision of informed consent prior to any study-specific procedures. * Male or female aged at least 18 years. * ECOG PS - 0/1-2. Exclusion Criteria: * Any concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of treatment. * Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.
Where this trial is running
Dallas, Texas
- Baylor Scott and White Research Institute — Dallas, Texas, United States (RECRUITING)
Study contacts
- Principal investigator: Ronan J Kelly, MD MBA — Chief of Oncology Baylor Scott & White Health System
- Study coordinator: Galit Yahalom, PhD
- Email: galit@oncohost.com
- Phone: 97248537557
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Non Small Cell Lung Cancer, Healthy